NEW YORK (GenomeWeb) – Appistry has raised approximately $4 million of a planned $8.6 million equity financing round, according to a document filed last week with the US Securities and Exchange Commission.
In an email to GenomeWeb this week, an Appistry spokesperson noted that the company raised the capital through its recent Series A financing, with Arsenal Capital Management leading the round.
The funding will be used for operations and engineering, with a focus on the continued development of Appistry's GenomePilot DNA data-analysis software. In addition, Appistry will use the funds to support "our expansion into RNA support and future product development in the area of genomic medical interpretation," the spokesperson said.
In May, St. Louis-based Appistry said it was partnering with Washington University in St. Louis to integrate WUSTL's VarScan variant-detection software into GenomePilot.
Earlier this month Appistry launched GenomePilot 4.0, which incorporates the ability to perform differential expression analysis of RNA-seq data.